journal
MENU ▼
Read by QxMD icon Read
search

Clinical and Experimental Rheumatology

journal
https://www.readbyqxmd.com/read/28516888/one-biopsy-two-diagnoses-statin-induced-autoimmune-myopathy-in-combination-with-extranodal-marginal-zone-lymphoma
#1
Stijn Michiels, Daan Dierickx, Veerle Taelman, Thomas Tousseyn, Jan Lenaerts, Ellen De Langhe
****************************************************************************.
May 17, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516887/tenosynovitis-in-rheumatoid-arthritis-patients-on-biologic-treatment-involvement-and-sensitivity-to-change-compared-to-joint-inflammation
#2
Hilde Berner Hammer, Tore K Kvien, Lene Terslev
OBJECTIVES: Extensor carpi ulnaris (ECU) and tibialis posterior (TP) tendons are often involved in RA and the present aim was to examine by ultrasound (US) their frequency of inflammation and sensitivity to change in comparison to joint involvement as well as clinical examinations. METHODS: US, clinical and laboratory assessments were performed when starting biologic DMARD (bDMARD) and after 1, 2, 3, 6 and 12 months including bilateral grey-scale (GS) and power Doppler (PD) semi-quantitatively (0-3) scoring of ECU and TP tendons and 18 joints...
May 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516885/rapid3-correlates-with-esspri-and-other-patient-reported-outcomes-in-patients-with-primary-sj%C3%A3-gren-s-syndrome
#3
Marja Pertovaara, Markku Korpela
****************************************************************************.
May 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516883/sarcoidosis-and-tocilizumab-is-there-a-link
#4
Lindsay Bustamente, Buscot Matthieu, Charles-Hugo Marquette, Christian Roux
****************************************************************************.
May 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516874/long-term-effects-of-interleukin-17a-inhibition-with-secukinumab-in-active-ankylosing-spondylitis-3-year-efficacy-and-safety-results-from-an-extension-of-the-phase-3-measure-1-trial
#5
Xenofon Baraliakos, Alan J Kivitz, Atul A Deodhar, Jürgen Braun, James C Wei, Eumorphia Maria Delicha, Zsolt Talloczy, Brian Porter
OBJECTIVES: Secukinumab, a fully human anti-IL-17A monoclonal antibody, provided rapid and sustained improvements in signs and symptoms of ankylosing spondylitis (AS) over 2 years in the Phase 3 MEASURE 1 trial. Here, we report efficacy and safety after 3 years of treatment. METHODS: AS subjects completing 2 years of treatment every 4 weeks with subcutaneous secukinumab 150 or 75 mg (following intravenous loading or initial placebo treatment to 16/24 weeks) entered a separate 3-year extension study (NCT01863732)...
May 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516872/glucocorticoid-sparing-effect-of-first-year-anti-tnf%C3%AE-treatment-in-rheumatoid-arthritis-corpus-cohort
#6
Carole Duquenne, Daniel Wendling, Jean Sibilia, Chantal Job-Deslandre, Loic Guillevin, Jacques Benichou, René Marc Flipo, Francis Guillemin, Alain Saraux
OBJECTIVES: Anti-TNFα agents are indicated in selected patients with rheumatoid arthritis (RA) who respond inadequately to methotrexate and particularly when glucocorticoids are mandatory. We evaluated whether a glucocorticoid-sparing effect occurred during the first year of anti-TNF-α therapy. METHODS: Between 2007 and 2009, the French multicentre, longitudinal, prospective, observational, population-based CORPUS cohort included biologic-naive patients with inflammatory joint disease...
May 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516890/tocilizumab-in-the-treatment-of-patients-with-rheumatoid-arthritis-in-real-clinical-practice-results-of-an-italian-observational-study
#7
Roberto Caporali, Luca Idolazzi, Stefano Bombardieri, Gianfranco Ferraccioli, Roberto Gerli, Marco Govoni, Marco Matucci Cerinic, Giovanni Pomponio, Fausto Salaffi, Rossella Tirri, Francesca Benaglio, Laura Bianchino, Piercarlo Sarzi-Puttini
OBJECTIVES: To describe the effectiveness and safety of tocilizumab (TCZ), an interleukin-6 receptor inhibitor, in a cohort of patients with rheumatoid arthritis (RA) recruited in clinical practice. METHODS: TRUST was an observational study in RA patients who started treatment with TCZ in the 6 months prior to site activation and were still on treatment at start of study; patients were followed up to 12 months after the first TCZ infusion. RESULTS: 322 RA patients were enrolled in 59 Italian centres (mean age: 55...
May 8, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516889/an-update-on-the-animal-models-in-hyperuricaemia-research
#8
REVIEW
Yantong Zhu, Xiaofei Peng, Guanghui Ling
Hyperuricaemia is a metabolic disease caused by purine metabolic abnormalities, mainly due to the increased formation or reduced excretion of uric acid. In recent years, it has been proved that hyperuricaemia is an important risk factor for chronic kidney disease (CKD) and cardiovascular disease, and it also takes part in the pathophysiology of metabolic syndrome. In addition, more attention has been concentrated on the pathogenesis or treatment of hyperuricaemia. Since establishing an animal model on hyperuricaemia is the foundation for further researches, several methods to establish the hyperuricaemia model have been developed...
May 8, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516882/interstitial-lung-disease-is-associated-to-infections-of-lower-respiratory-tract-in-immunocompromised-rheumatoid-arthritis-patients
#9
Marco Sebastiani, Andreina Manfredi, Giulia Cassone, Gilda Sandri, Stefania Cerri, Clodoveo Ferri
****************************************************************************.
May 8, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516881/exploring-the-remission-concept-in-rheumatoid-arthritis-with-patients-and-rheumatologists-time-for-a-new-approach
#10
Carlos Acebes, José Luis Andreu, Alejandro Balsa, Enrique Battle, Javier de Toro-Santos, Francisco García Llorente, María Victoria Hernández, Benjamín Fernández-Gutiérrez, Cristina Hidalgo-Calleja, Lucía Mayordomo, Esperanza Naredo, Francisco Javier Narváez, Ana M Ortiz, José Luis Pablos, Trinidad Pérez-Sandoval, Carlos Rodríguez-Lozano, Olga Sánchez-Pernaute, Jacqueline Usón, José B Negrón, Estibaliz Loza, Loreto Carmona, Susana Gómez Castro, María Montoro Alvarez
OBJECTIVES: To explore the remission concept in rheumatoid arthritis (RA) and to compare remission definitions and related concepts between rheumatologists and patients with the purpose of identifying similarities and disparities to comprehend the different perspectives of the disease. METHODS: This was a qualitative study of discourse and content analysis through focus groups, conducted from February to March 2016. Four focus groups were set up, each one with different interests: rheumatologists involved in basic research (BR), rheumatologists with high specialisation in imaging techniques (IR), clinical rheumatologists (CR), and patients (PA)...
May 8, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516879/comparison-of-efficacy-of-first-versus-second-line-adalimumab-in-patients-with-rheumatoid-arthritis-experience-of-the-italian-biologics-registries
#11
Veronica Codullo, Florenzo Iannone, Luigi Sinigaglia, Ennio Giulio Favalli, Piercarlo Sarzi-Puttini, Fabiola Atzeni, Gianfranco Ferraccioli, Elisa Gremese, Antonio Carletto, Alessandro Giollo, Marcello Govoni, Francesca Bergossi, Mauro Galeazzi, Luca Cantarini, Fausto Salaffi, Marco Di Carlo, Chiara Bazzani, Raffaele Pellerito, Marco Sebastiani, Roberta Ramonda, Giovanni Lapadula, Roberto Caporali
OBJECTIVES: Targeted drugs against key pathogenetic molecules such as TNF-alpha have significantly improved outcomes in rheumatoid arthritis (RA). They are widely used in clinical practice and drug registries give us information to support their use. Adalimumab (ADA) is able to induce a comprehensive disease control in RA by achieving clinical, functional and radiographic control. METHODS: By interrogating 2 Italian registries, LORHEN and GISEA, we analysed the efficacy of ADA in first- or second-line in a total of 2262 RA patients...
May 8, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516877/validity-of-the-workers-productivity-and-activity-impairment-questionnaire-specific-health-problem-wpai-shp-in-patients-with-systemic-sclerosis
#12
Kathleen Morrisroe, Wendy Stevens, Molla Huq, Joanne Sahhar, Gene-Siew Ngian, Jane Zochling, Janet Roddy, Susanna M Proudman, Mandana Nikpour
OBJECTIVES: To evaluate the construct validity of the Workers Productivity and Impairment Activity Index: Specific Health Problem (WPAI:SHP) in Australian systemic sclerosis (SSc) patients. METHODS: SSc patients, identified through the Australian Scleroderma Cohort Study database, completed the WPAI:SHP and a quality of life instrument (PROMIS-29) cross-sectionally. The construct validity of the WPAI:SHP was assessed by the correlations between the WPAI:SHP and a range of SSc health states...
May 8, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516871/diagnosis-of-catastrophic-anti-phospholipid-syndrome-in-a-patient-tested-negative-for-conventional-tests
#13
Fabrizio Conti, Roberta Priori, Cristiano Alessandri, Roberta Misasi, Antonella Capozzi, Monica Pendolino, Simona Truglia, Silvia Frisenda, Maurizio Sorice, Guido Valesini
Catastrophic antiphospholipid syndrome (CAPS) is a severe variant of APS, characterised by clinical evidence of multiple organ involvement developing over a very short period of time, histopathological evidence of multiple small vessel occlusions and laboratory confirmation of the presence of aPL (lupus anticoagulant and/or anticardiolipin antibodies and/or anti-Beta2-glcyoprotein I antibodies). Here we report a case of a 39-year-old woman patient who developed a CAPS which was negative to the conventional aPL but positive for aPL in thin layer chromatography immunostaining and vimentin/cardiolipin antibodies by ELISA test...
May 8, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516870/the-relevance-of-cluster-analyses-to-stratify-systemic-lupus-erythematosus-increased-mortality-with-heavier-treatment
#14
Ginevra De Marchi, Luca Quartuccio, Francesca Zuliani, Milena Bond, Salvatore De Vita
****************************************************************************.
May 8, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516869/recommendations-for-infectious-disease-screening-in-migrants-to-western-europe-with-inflammatory-arthropathies-before-starting-biologic-agents-results-from-a-multidisciplinary-task-force-of-four-european-societies-sir-ser-simet-semtsi-facing-the-lar
#15
Filippo Bartalesi, Carlo Scirè, Ana Requena-Méndez, Miguel Angel Abad, Dora Buonfrate, Roberto Caporali, Fabrizio Conti, Federico Diaz-Gonzalez, Cruz Fernández-Espartero, Carmen Martinez-Fernandez, Marta Mascarello, Elena Generali, Giovanni Minisola, Aldo Morrone, Jose Muñoz, Patricia Richi, Gariffalia Sakellariou, Joaquin Salas Coronas, Michele Spinicci, Francesco Castelli, Alessandro Bartoloni, Zeno Bisoffi, Francisco Gimenez-Sanchez, Santiago Muñoz-Fernandez, Marco Matucci-Cerinic
OBJECTIVES: Inflammatory arthritis needs infectious disease screening before starting a biologic agent, however, few data are known about migrant patients, who represent a peculiar population which requires a multidisciplinary approach among international health specialists and should also be considered by health authorities. For this reason, the Italian and Spanish Societies of Rheumatology (SIR and SER) and Tropical Medicine (SIMET and SEMTSI) promoted a multidisciplinary task force in order to produce specific recommendations about screening and advices to be considered in migrant patients with inflammatory arthritis candidate to receive biological therapy, according to their geographical origin...
May 8, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516868/predicting-responses-in-patients-with-rheumatoid-arthritis-to-disease-modifying-agents-using-baseline-clinical-data
#16
Nicola J Gullick, Aneela N Mian, Fowzia Ibrahim, David Walker, Andrew Hassell, Patrick D W Kiely, David A Walsh, Adam Young, David L Scott
OBJECTIVES: The optimal treatment for active rheumatoid arthritis (RA) is unresolved, particularly in early RA. We used data from an observational cohort to develop the simple predictor algorithm and evaluated its application in two completed clinical trials in early and established RA. We assessed whether using a simple algorithm can identify patients who have persisting active disease despite treatment with disease-modifying drugs (DMARDs). We also examined if patients who have lower likelihoods of persisting active RA are likely to benefit from intensive treatment...
May 8, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516867/the-link-between-proteus-mirabilis-environmental-factors-and-autoantibodies-in-rheumatoid-arthritis
#17
REVIEW
Taha Rashid, Alan Ebringer, Clyde Wilson
Rheumatoid arthritis (RA) is a relatively common and potentially disabling immune-mediated inflammatory systemic disease, predominantly affecting women and characterised by multiple small joint arthritis. Extensive data supports the roles of genetic, environmental and microbial factors in the triggering and development of this disease. Proteus mirabilis is considered as the main microbial culprit in the causation of RA. The evidence for the role of these microbes in RA and their links with commonly associated autoantibodies such as rheumatoid factors and anti-citrullinated peptide antibodies have been elucidated together with their relations with some of the non-microbial environmental factors which have been implicated in the aetiopathogenesis of RA...
May 8, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516884/patient-participation-in-patient-reported-outcome-instrument-development-in-systemic-sclerosis
#18
REVIEW
John D Pauling, Tracy M Frech, Robyn T Domsic, Marie Hudson
OBJECTIVES: The patient perspective captured using Patient-Reported Outcome (PRO) instruments provide insight into the patient condition not always captured by physician-derived assessment tools. Target patient population involvement is an essential component of PRO instrument development. We have reviewed the level of patient involvement in the development of PRO instruments used in the assessment of systemic sclerosis (SSc). METHODS: A comprehensive literature review was undertaken to identify studies reporting PRO instruments in SSc...
May 2, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516878/high-incidence-of-vertebral-osteoporotic-fracture-within-the-first-year-after-liver-transplantation
#19
Sarah Butin, Isabelle Griffoul, Fabien Espitalier, Ephrem Salamé, Denis Mulleman, Philippe Goupille
OBJECTIVES: Bone loss is a complication for patients with liver diseases and after transplantation, which results in increased fracture risk. The aim of this study was to determine the incidence of osteoporotic vertebral fractures following liver transplantation. METHODS: We performed a prospective study of patients who were awaiting liver transplantation. Patients were seen at baseline (visit 1) and one year after transplantation (visit 2). At each visit, risk factors of osteoporosis were collected, biochemical tests were performed and bone mineral density with Vertebral Fracture Assessment was assessed...
April 29, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28516886/patterns-of-tocilizumab-use-effectiveness-and-safety-in-patients-with-rheumatoid-arthritis-core-data-results-from-a-set-of-multinational-observational-studies
#20
Bolous Haraoui, Gustavo Casado, Laszlo Czirják, Andrew Taylor, Corrado Bernasconi, William Reiss, Roberto Caporali
OBJECTIVES: To observe patients with rheumatoid arthritis (RA) treated with the interleukin-6 receptor-alpha inhibitor tocilizumab (TCZ) in routine clinical practice. METHODS: Data on concomitant medications, effectiveness and safety were pooled from independent, multinational studies in patients with RA initiating intravenous TCZ according to local label recommendations observed in routine practice for 6 months. Patients were grouped by TCZ monotherapy or combination therapy with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs)...
April 28, 2017: Clinical and Experimental Rheumatology
journal
journal
20072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"